These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17244883)

  • 1. Anemia in cancer and critical care patients: pharmacoeconomic considerations.
    Reeder CE
    Am J Health Syst Pharm; 2007 Feb; 64(3 Suppl 2):S22-7; quiz S28-30. PubMed ID: 17244883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
    Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
    Oberhoff C
    Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
    Vekeman F; McKenzie RS; Lefebvre P; Watson SH; Mody SH; Piech CT; Duh MS
    Am J Health Syst Pharm; 2007 Sep; 64(18):1943-9. PubMed ID: 17823106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietic agents for anemia of critical illness.
    Shermock KM; Horn E; Rice TL
    Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system.
    Adamson R; Lew I; Allen P; Misuro A; Malacrida P
    Am J Health Syst Pharm; 2005 Nov; 62(22):2416-9. PubMed ID: 16278336
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
    Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
    Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z; DeSantis ER
    Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic impact of epoetins in cancer care.
    Marchetti M; Barosi G
    Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC; Saglimbene V; Craig JC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009297. PubMed ID: 24683046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.